Changes are afoot at foundering Teva—and they include layoffs and a hiring freeze.

When PTC agreed to buy Marathon's Emflaza last week, it inherited congressional scrutiny on the drug's price, originally set at a much-lambasted $89,…

​​​​​​​After taking a beating over a proposed Zika vaccine license from the U.S. Army, Sanofi is hitting back.

New England Compounding Center's contaminated drugs caused a fungal meningitis outbreak that killed more than 60 people.

Pharma patent challenger Kyle Bass has lost his second round at the U.S. Patent and Trademark Office in as many weeks, and this time, the win is Biogen’s.

U.S. government watchdogs plan to probe the FDA's orphan drug policies after Marathon's high-profile pricing scandal.

​​​​​​​An add-on Parkinson’s med already available in various countries throughout Europe will soon make its way to U.S. patients.

Johnson & Johnson’s new sponsorship of “Give a Spit for Cancer” features comedian Hannibal Buress in the ongoing drive to register potential bone marrow…

In 2016, many pharma marketers embraced disease awareness and charitable causes to drive better consumer engagement across social networks, according to a new…